Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
about
Allogenic banking of dental pulp stem cells for innovative therapeuticsBottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal CellsMesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challengescGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.Manufacturing and banking of mesenchymal stem cells.Tissue engineering and regenerative medicine: semantic considerations for an evolving paradigm.Clinical research skills development program in cell-based regenerative medicine.Mesenchymal stem cells: are we ready for clinical application in transplantation and tissue regeneration?Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.Regulation of cell-based therapies in Europe: current challenges and emerging issuesConcise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?The emerging use of bone marrow-derived mesenchymal stem cells in the treatment of human chronic wounds.Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.Concepts in regenerative medicine: Past, present, and future in articular cartilage treatment.Cellular Therapies for Treatment of Radiation Injury after a Mass Casualty Incident.Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency.Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization
P2860
Q26795542-3F5C5220-5365-43B0-AB43-BFB700C9B461Q26798278-4F0CDD20-F5EC-49F1-84E9-83A769007150Q30009860-D851F078-912C-4157-A1C6-809EFC17DDCAQ34045021-9B8CD4DE-2C71-4502-8068-3972CCF70232Q34323739-1F90A8A0-55D7-48E5-9D4B-8E8ACC17AB30Q34913995-3B5C25C4-F407-4BF3-BCD0-D2A543F1AAC8Q35001367-D54AD5C0-18FF-4425-BD6E-4D3B4F0DC1D2Q36917428-3F5582F1-F7C0-415B-B3AE-239F5C9814B1Q37079961-9537FAEF-4820-462B-8E89-D543FA7C1B46Q37442918-2D5DF527-A346-4377-AFDD-AB3005694F74Q38114405-281F6569-C5E3-4C5E-A604-5BCEF345B4C6Q38134137-99CBB740-7BAA-4BDD-9AB5-338C493AAFFAQ38730028-08EF0CAD-2F12-4D7C-9F49-AB924731861FQ38834712-2CB31231-F3E0-4DA0-BD35-2385A315119CQ40174306-1C49B719-34CB-4E62-B193-A457906F9525Q44794582-2C7E5B5A-7459-4A6D-B07C-DBD9B766C201Q58855503-A6867589-DC37-4D23-AEF3-DC059D4F4096
P2860
Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cell therapy medicinal product ...... MSC-based therapy development.
@ast
Cell therapy medicinal product ...... MSC-based therapy development.
@en
type
label
Cell therapy medicinal product ...... MSC-based therapy development.
@ast
Cell therapy medicinal product ...... MSC-based therapy development.
@en
prefLabel
Cell therapy medicinal product ...... MSC-based therapy development.
@ast
Cell therapy medicinal product ...... MSC-based therapy development.
@en
P2860
P356
P1476
Cell therapy medicinal product ...... MSC-based therapy development.
@en
P2093
Janis Ancans
P2860
P356
10.3389/FIMMU.2012.00253
P577
2012-08-14T00:00:00Z